As groundbreaking studies continue to reshape the human immunodeficiency virus (HIV) landscape, emerging therapies and ...
GlobalData on MSN2d
Gilead and MSD to advance once-weekly HIV treatment to Phase IIIThe companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Generic tenofovir disoproxil fumarate/emtricitabine the most frequently prescribed medication since 2021. (HealthDay News) — Preexposure prophylaxis (PrEP) use increased between 2013 and 2023, ...
Zacks.com on MSN3d
Gilead, MRK Report Data From Investigational Combination Study for HIVGilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...
Preexposure prophylaxis (PrEP) use increased between 2013 and 2023, according to a research letter published online Oct. 14 ...
The Biden-Harris administration has a historic opportunity to help end HIV. New, cutting-edge drugs that prevent HIV are ...
Indigenous communities in Latin America say they are being excluded from the global HIV/AIDS response, leaving them without ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback